Dosimetry-Guided Radiopharmaceutical Therapy (DG-RPT)

Fighting Cancer.
Making it Personal.

WHY IT MATTERS

For cancer patients, personalized radiopharmaceutical therapy (RPT) can mean increased tumor response, a higher quality of life and longer overall survival.

The Advantages of Dosimetry-Guided RPT

RPT provides an attractive alternative to chemotherapy, but one-size-fits-all dosing methods can result in under- or over-treatment. Dosimetry-guidance can unlock the full potential of RPT for patients.

Maximum toxicity to tumors.

Reduced damage to critical structures.

Improved survival.

Fewer side effects.

Maximum toxicity to tumors.

Reduced damage to critical structures.

Improved survival.

Fewer side effects.

See How We're Improving RPT

Torch

GPU-Accelerated RPT Dose Assessment

Torch™ simplifies the otherwise complex task of analyzing a patient’s nuclear medicine scans to develop a personalized assessment, including estimates of patient-specific pharmacokinetics and calculation of dose to the patient’s tumors and critical structures. *

* 510(k) pending. Torch™ is under FDA review and is NOT available for sale or clinical use.

NEWS & WEBINARS

Voximetry selected as finalist for the 2022 Wisconsin Innovation Awards
Voximetry will be at Theranostics World Congress, Wiesbaden Germany